Olympus, Major Management Shakeup

Olympus has made a significant adjustment in its operating model.

01

Management streamlining

Organizational change is ongoing.

On April 1 local time, Olympus announced several personnel changes. These leadership changes are part of Olympus's new global strategy and operating model and took effect on April 1.

Richard Reynolds, formerly President of Olympus America Inc. (OAI)’s Medical Systems Group, has assumed the role of President of Olympus Americas, while Julien Sauvagnargues, formerly President and CEO of Olympus Corporation of the Americas (OCA), has decided to leave Olympus.

As part of its new operating model, Olympus has streamlined its leadership operations, appointing a president for each of the company's five global regions, all of whom report to Bob White, Director, Representative Executive Officer, President and CEO of Olympus Corporation.

Richard Reynolds joined Olympus in 1995 and held leadership positions in the UK, Europe, the Middle East, and Africa. In 2011, he moved to the United States and joined OCA, where he held various senior positions, including Executive Vice President of Sales, Vice President of Business Operations and the Service Group, and most recently President of the OAI Medical Systems Group.

Richard said, "Olympus is ready to set the standard for next-generation endoscope-assisted healthcare services through strategies such as integrating breakthrough technologies like artificial intelligence and robotics into our product portfolio. I am very much looking forward to leveraging my experience to guide our sales and operations teams in the Americas region in leading this effort."

According to Olympus's previous disclosure, the company has recently undergone several management changes.

Previously, Keith Boettiger served as a senior executive and co-leader of the Gastrointestinal Solutions division. Starting April 1, he will take on the role of Chief Executive Officer and head of the Gastrointestinal Solutions division. He succeeds Frank Drewalowski, who will transition to the role of Senior Advisor to the Chief Executive Officer, providing support for Olympus' strategic priorities.

Olympus former CEO Yasuo Takeuchi stepped down at the end of March from his roles as Representative Executive Officer, Executive Chairman, and Officer in charge of Environment, Social, and Governance, concluding his 40-year tenure with the company.

Olympus ranked 19th in the latest Global Top 100 Medical Device Companies list published by the renowned medical device industry website MD+DI.

The latest financial report of the company shows that from April 1, 2025, to December 31, 2025, Olympus' revenue was 715.4 billion yen, a decrease of 1.4% year-on-year. The operating profit for the period was 70.3 billion yen, a decrease of 35.4% year-on-year. The net profit attributable to the company for the period was 43.4 billion yen, a decrease of 43.2% year-on-year.

02

Global workforce reduction of 2,000 employees

Olympus Enters Strategic Transformation Period

Olympus, a leader in endoscopy, is undergoing a significant strategic transformation.

Last June, Bob White, former Executive Vice President and President of the Medtronic Interventional and Surgical Portfolio, succeeded Yasuo Takeuchi as CEO of Olympus.

In the same November, Olympus announced a new corporate strategy.

These include three strategic pillars: innovation-driven growth, simplification, and accountability. Moving forward, Olympus will strive to expand its leadership in AI-powered endoscopy, robotics, and cloud-connected solutions. At the same time, it will streamline processes, enhance team capabilities, and advance sustainability.

Olympus expects its Integrated Growth and Transformation Plan to deliver sustained value for patients, healthcare providers, and shareholders. The company aims to achieve 5% year-over-year revenue growth in fiscal year 2029, with 100 basis points of annual improvement starting from fiscal year 2026, a compound annual growth rate (CAGR) of earnings per share (EPS) exceeding 10%, and continued enhancement of free cash flow. Olympus will dynamically allocate capital to support innovation, dividends, share buybacks, and strategic acquisitions.

Currently, the global healthcare market environment is becoming more complex and industry competition is intensifying. It remains to be seen whether Olympus can break through its current growth constraints and achieve new development through internal transformation.